Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week Open Label, Basket Study of the safety, tolerability and treatment responses of SLS-005 (Trehalose Injection 90.5 mg/mL Intravenous Infusion) in Adults with Neurodegenerative Diseases

Next Previous
Search
Trial Profile

A 24-week Open Label, Basket Study of the safety, tolerability and treatment responses of SLS-005 (Trehalose Injection 90.5 mg/mL Intravenous Infusion) in Adults with Neurodegenerative Diseases

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trehalose (Primary)
  • Indications Amyotrophic lateral sclerosis; Huntington's disease; Spinocerebellar ataxias
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seelos Therapeutics

    • Most Recent Events

    • 27 Oct 2023 According to a Seelos Therapeutics media release, company announced that it has been selected to present a poster from a study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in a tauopathy model of Alzheimer's disease at the Society for Neuroscience's Neuroscience 2023 meeting, to be held on November 11-15, 2023, at the Walter E. Washington Convention Center in Washington, D.C.
    • 18 Jul 2022 According to a Seelos Therapeutics media release, first patient has been dosed in this study.
    • 18 Jul 2022 Status changed from not yet recruiting to recruiting, according to a Seelos Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top